We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Obviously, Dupixent in COPD has a broader label ... They overlap ever so slightly, I think, in the above 300 EOS level in the Type 2 COPD patient population. But I think the compliment of the ...

Dupixent is an eczema treatment whose rights ... and management of various kinds of cancers. Its 300-plus Vysis DNA FISH probes are specially designed for breast, hematology, bladder, lung ...

The lung disease affects more than 300 million people globally ... Sanofi and Regeneron's big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease ...

COPD affects more than 300 million people globally and is the ... For Nucala, is the exacerbation data competitive with Dupixent and have you shown an FEV benefit, I mean, if not, your statements ...

In the BOREAS and NOTUS trials, Dupixent cut the rate of exacerbations by 30% and 34%, respectively, and both those studies specifically enrolled patients with BEC levels of 300 cells/μL or above.

Chronic obstructive pulmonary disease (COPD) is a significant global health concern, ranking as the third-leading cause of mortality worldwide and affecting around 480 million people. 1,2 Its hallmark ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...